Rapid early hematological response in a newly diagnosed patient with very severe aplastic anemia: a case report of high-dose romiplostim, hetrombopag and IST combination therapy - Takeaways - MDSpire

Rapid early hematological response in a newly diagnosed patient with very severe aplastic anemia: a case report of high-dose romiplostim, hetrombopag and IST combination therapy

  • By

  • Liangkui Luo

  • Kaikai Huang

  • Yanbin Pang

  • May 25, 2026

Share

  • 1

    Very severe aplastic anemia (VSAA) is a critical condition requiring rapid treatment responses, especially for patients ineligible for HSCT.

  • 2

    A 16-year-old male with newly diagnosed VSAA achieved complete remission after treatment with high-dose romiplostim, hetrombopag, and immunosuppressive therapy.

  • 3

    The patient experienced a partial trilineage response by week 9 and complete remission by week 22, with sustained remission after 7 months.

  • 4

    The combination therapy resulted in transfusion independence and minimal adverse effects, indicating a promising treatment approach for VSAA.

  • 5

    This case suggests that dual TPO-RA therapy may be a viable first-line option for HSCT-ineligible patients with VSAA, warranting further investigation.

Original Source(s)

Rapid early hematological response in a newly diagnosed patient with very severe aplastic anemia: a case report of high-dose romiplostim, hetrombopag and IST combination therapy

  • by Liangkui Luo, Kaikai Huang, Yanbin Pang

  • May 25, 2026

Related Content

Rare COVID Vaccine Clotting Linked to Adenoviral Protein

Antibody proteomics and immunogenetics identify adenoviral protein VII as the trigger of PF4-targeting antibodies

  • May 13, 2026

  • 3 min
Complex Hematologic Malignancy Management in a TP53-Mutated Patient: Balancing Disease Control and Quality of Life

Cytogenetic and molecular testing revealed a complex karyotype and a TP53 mutation, placing her disease in an adverse-risk category.

  • by

  • April 27, 2026

  • 5 min
Stuart Orkin Awarded Breakthrough Prize in Life Sciences

Stuart H. Orkin, MD, Investigator at Dana-Farber/Boston Children's Cancer and Blood Disorders Center, David G. Nathan Distinguished Professor, Harvard Medical School and Investigator, Howard Hughes Medical Institute, has been honored with The Breakthrough Prize in Life Sciences for discovering how the body turns off fetal hemoglobin after birth, a finding that led to a new treatment strategy for sickle cell disease. Dr. Orkin shares the prize with SweeLay Thein, Investigator at the National Institutes of Health (NIH).

  • by

  • April 19, 2026

  • 6 min